Unfavorable Outcome of Neuroblastoma in Patients With 2p Gain
Background: Amplification of the MYCN oncogene is the most unfavorable genetic factor in neuroblastoma patients. However, knowledge about the clinical impact of low-level multiplication of MYCN is still insufficient. Therefore, we aimed to investigate the disease course in patients with different co...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.01018/full |
| _version_ | 1828164509482614784 |
|---|---|
| author | Katarzyna Szewczyk Aleksandra Wieczorek Aleksandra Wieczorek Wojciech Młynarski Szymon Janczar Mariola Woszczyk Zuzanna Gamrot Radosław Chaber Mariusz Wysocki Monika Pogorzała Mirosław Bik-Multanowski Walentyna Balwierz Walentyna Balwierz |
| author_facet | Katarzyna Szewczyk Aleksandra Wieczorek Aleksandra Wieczorek Wojciech Młynarski Szymon Janczar Mariola Woszczyk Zuzanna Gamrot Radosław Chaber Mariusz Wysocki Monika Pogorzała Mirosław Bik-Multanowski Walentyna Balwierz Walentyna Balwierz |
| author_sort | Katarzyna Szewczyk |
| collection | DOAJ |
| description | Background: Amplification of the MYCN oncogene is the most unfavorable genetic factor in neuroblastoma patients. However, knowledge about the clinical impact of low-level multiplication of MYCN is still insufficient. Therefore, we aimed to investigate the disease course in patients with different copy number status of MYCN.Materials and Methods: We examined 105 children diagnosed with neuroblastoma from 2010 to 2018 in five pediatric oncology centers in Poland. We determined the MYCN status at diagnosis by the interphase FISH examination and assessed the clinical outcome in patients.Results: A total of 35% of tumors presented with chromosome 2 numerical changes, 20% had MYCN amplification and 16% revealed 2p gain. Unexpectedly, we observed very low overall survival and event free survival (EFS) rates in neuroblastomas with 2p gain, which were comparable with patients with MYCN amplification.Conclusions: The 2p gain alteration should be reported as a strong unfavorable prognostic marker in neuroblastoma patients. |
| first_indexed | 2024-04-12T01:27:35Z |
| format | Article |
| id | doaj.art-acfceea22ade44d58702c884d80f094f |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T01:27:35Z |
| publishDate | 2019-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-acfceea22ade44d58702c884d80f094f2022-12-22T03:53:34ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2019-10-01910.3389/fonc.2019.01018478353Unfavorable Outcome of Neuroblastoma in Patients With 2p GainKatarzyna Szewczyk0Aleksandra Wieczorek1Aleksandra Wieczorek2Wojciech Młynarski3Szymon Janczar4Mariola Woszczyk5Zuzanna Gamrot6Radosław Chaber7Mariusz Wysocki8Monika Pogorzała9Mirosław Bik-Multanowski10Walentyna Balwierz11Walentyna Balwierz12Department of Medical Genetics, Faculty of Medicine, Jagiellonian University Medical College, Krakow, PolandDepartment of Pediatrics Oncology and Hematology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, PolandDepartment of Pediatric Oncology and Hematology, University Children's Hospital of Krakow, Krakow, PolandDepartment of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Lodz, PolandDepartment of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Lodz, PolandUnit of Pediatric Oncology and Hematology, City Hospital, Chorzow, PolandUnit of Pediatric Oncology and Hematology, City Hospital, Chorzow, PolandClinic of Pediatric Oncology and Hematology, Faculty of Medicine, University of Rzeszow, Rzeszow, PolandDepartment of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandDepartment of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandDepartment of Medical Genetics, Faculty of Medicine, Jagiellonian University Medical College, Krakow, PolandDepartment of Pediatrics Oncology and Hematology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, PolandDepartment of Pediatric Oncology and Hematology, University Children's Hospital of Krakow, Krakow, PolandBackground: Amplification of the MYCN oncogene is the most unfavorable genetic factor in neuroblastoma patients. However, knowledge about the clinical impact of low-level multiplication of MYCN is still insufficient. Therefore, we aimed to investigate the disease course in patients with different copy number status of MYCN.Materials and Methods: We examined 105 children diagnosed with neuroblastoma from 2010 to 2018 in five pediatric oncology centers in Poland. We determined the MYCN status at diagnosis by the interphase FISH examination and assessed the clinical outcome in patients.Results: A total of 35% of tumors presented with chromosome 2 numerical changes, 20% had MYCN amplification and 16% revealed 2p gain. Unexpectedly, we observed very low overall survival and event free survival (EFS) rates in neuroblastomas with 2p gain, which were comparable with patients with MYCN amplification.Conclusions: The 2p gain alteration should be reported as a strong unfavorable prognostic marker in neuroblastoma patients.https://www.frontiersin.org/article/10.3389/fonc.2019.01018/full2p gainMYCN gainMYCN amplificationneuroblastomastructural chromosomal aberrations |
| spellingShingle | Katarzyna Szewczyk Aleksandra Wieczorek Aleksandra Wieczorek Wojciech Młynarski Szymon Janczar Mariola Woszczyk Zuzanna Gamrot Radosław Chaber Mariusz Wysocki Monika Pogorzała Mirosław Bik-Multanowski Walentyna Balwierz Walentyna Balwierz Unfavorable Outcome of Neuroblastoma in Patients With 2p Gain Frontiers in Oncology 2p gain MYCN gain MYCN amplification neuroblastoma structural chromosomal aberrations |
| title | Unfavorable Outcome of Neuroblastoma in Patients With 2p Gain |
| title_full | Unfavorable Outcome of Neuroblastoma in Patients With 2p Gain |
| title_fullStr | Unfavorable Outcome of Neuroblastoma in Patients With 2p Gain |
| title_full_unstemmed | Unfavorable Outcome of Neuroblastoma in Patients With 2p Gain |
| title_short | Unfavorable Outcome of Neuroblastoma in Patients With 2p Gain |
| title_sort | unfavorable outcome of neuroblastoma in patients with 2p gain |
| topic | 2p gain MYCN gain MYCN amplification neuroblastoma structural chromosomal aberrations |
| url | https://www.frontiersin.org/article/10.3389/fonc.2019.01018/full |
| work_keys_str_mv | AT katarzynaszewczyk unfavorableoutcomeofneuroblastomainpatientswith2pgain AT aleksandrawieczorek unfavorableoutcomeofneuroblastomainpatientswith2pgain AT aleksandrawieczorek unfavorableoutcomeofneuroblastomainpatientswith2pgain AT wojciechmłynarski unfavorableoutcomeofneuroblastomainpatientswith2pgain AT szymonjanczar unfavorableoutcomeofneuroblastomainpatientswith2pgain AT mariolawoszczyk unfavorableoutcomeofneuroblastomainpatientswith2pgain AT zuzannagamrot unfavorableoutcomeofneuroblastomainpatientswith2pgain AT radosławchaber unfavorableoutcomeofneuroblastomainpatientswith2pgain AT mariuszwysocki unfavorableoutcomeofneuroblastomainpatientswith2pgain AT monikapogorzała unfavorableoutcomeofneuroblastomainpatientswith2pgain AT mirosławbikmultanowski unfavorableoutcomeofneuroblastomainpatientswith2pgain AT walentynabalwierz unfavorableoutcomeofneuroblastomainpatientswith2pgain AT walentynabalwierz unfavorableoutcomeofneuroblastomainpatientswith2pgain |